Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
-
Notable Analyst Rating Changes 10/20: NIHD, MOS, JNPR, SYK Upgraded; AMLN, BAC, FSII, WDC Downgraded
-
Trading Radar for 10/20: Morgan Stanley (MS), US Bancorp (USB), Delta Air (DAL), eBay (EBAY), Xilinx (LNX) Report
-
Trading Radar for 07/21: Coca-Cola (KO), eBay (EBAY), Baidu.com (BIDU), Qualcomm (QCOM) Report
-
Notable Analyst Rating Changes 06/21: PLD, TC, AMLN, PLCM Upgraded; AFFY, TMRK, MDAS, LAZ Downgraded
-
Unusual 11 Mid-Day Movers 06/18: CWLZ, MIPI, PESI, AMLN, AIB, ENTR Higher; ADLR, BANR, WBD, IFLG, GMTC Lower
-
Roche's Taspoglutide Setback Gives Amylin (AMLN) A Boost
-
Morning Movers 6/18: CWLZ, NMTI, AMLN, ALKS Higher; GMTC, ADLR, BANR Lower
-
JPMorgan Raises Amylin (AMLN) to Overweight Following Taspo Delay
-
Amylin (AMLN) Jumps On Taspo Delay
-
Piper Jaffray Said Taspo Delays A Positive for Amylin (AMLN)
-
Notable Analyst Rating Changes 06/14: CRNT, JBLU, AMLN, HIG Upgraded; AKAM, ISRG, DO, ARCL Downgraded
-
Piper Jaffray Upgrades Amylin Pharmaceuticals (AMLN) to Overweight; Valuation and Best in Class Profile of Bydureon
-
Notable Analyst Rating Changes 03/29: SWN, SVR, CBG, SOLF, SYUT Upgraded; SNV, DRC, TAP, PEET Downgraded
-
Piper Jaffray Initiates Coverage on Amylin Pharmaceutical (AMLN) with a Neutral; Taspoglutide's Safety Could Determine Bydureon's Success
-
Notable Analyst Rating Changes 03/11: DPS, LVLT, PRA Upgraded; YHOO, SKIL, BBBY, MT, SLG Downgraded
-
Notable Analyst Rating Changes 03/03: KO, DIS, BA, ZUMZ Upgraded; AMLN, FITB, MDVN, CBEY Downgraded
-
Notable Analyst Rating Changes 03/03: UPS, SLB, INAP, YSI, FCX Upgraded; NFLX, VISN, MDVN, HELE Downgraded
-
Trading Radar for 01/27: ConocoPhillips (COP), Boeing (BA), Abbott (ABT), General Dynamics (GD), E*TRADE (ETFC) Report
-
Amylin (AMLN) Tumbles as Competitor to Byetta, Novo Nordisk's liraglutide, Does Not Receive FDA Recommendation
-
David Moenning's Daily State of the Markets: 10/22
-
Wall Street Throws In the Towel On Amylin (AMLN) Following New Byetta Patient Deaths
-
Piper Jaffray Believes the Street Overreacted to Amylin's (AMLN) Pancreatitis Update
-
David Moenning's Daily State of the Markets: 7/22
-
Notable Analyst Rating Changes 6/9: MVSN, MUR, ETN Upgraded; AMLN, LL, FTO Downgraded
-
Piper Jaffray Adds Amylin Pharma. (AMLN) to Alpha List
